drugset
drugset / Trial / NCT04923607

Phase I Clinical Trial of TQC2731 Injection

NCT04923607 ↗

Phase 1 Unknown 96 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.

Timeline

Start
2021-06-25
Primary completion
2023-08-25
Completion
2023-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject TQC2731 Monoclonal antibody 12 mg Subcutaneous
Subject TQC2731 Monoclonal antibody 70 mg Subcutaneous
Subject TQC2731 Monoclonal antibody 105 mg Subcutaneous
Subject TQC2731 Monoclonal antibody 210 mg Subcutaneous
Subject TQC2731 Monoclonal antibody 280 mg Subcutaneous
Subject TQC2731 Monoclonal antibody 420 mg Subcutaneous
Subject TQC2731 Monoclonal antibody 630 mg Subcutaneous

Indications

chronic asthma